Three of our products are ready to begin clinical trials to gather human data:

Blu-T® (ITL-1636) is a breast cancer diagnostic tool designed to amplify mammography signals by 100 times, allowing the detection of very small ductal carcinomas. In addition, the treatment turns the tumor cells the color aqua-marine, for precise surgical removal.

Parkinol® (ITL-1634) is designed to treat Parkinson’s Disease. It is a new molecular entity designed to arrest the root cause of cell death in the central nervous system in Parkinson’s patients. It is designed to stop disease progression and may be curative.

ThyroMax® (ITL-1834) is designed to treat hypothyroidism. It has also shown results in treating depression and hypometabolism. Its sustained release profile allows once-per-day dosing and provides superior clinical management of hypothyroid symptoms compared to T4 replacement therapy alone.

Each of these products could make a difference in the lives of thousands, and even millions, relatively soon.

For more information, contact clinicaltrials@itlpharma.com.